Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 9:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lipoprotein Disorder Clear all
Recruiting Early Phase 1 Interventional

Differential Thrombogenesis by EPA and DHA Mediated by HDL

NCT06494488
View directory record Official record
Conditions
Lipid Metabolism Disorders, Hypertriglyceridemia
Interventions
EPA, DHA
Drug
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 69 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 20, 2026, 9:21 AM EDT
Completed Phase 2 Interventional Results available

Blood Lipopolysaccharide (LPS) Rifaximin Study

NCT02124512
View directory record Official record
Conditions
Obese, Insulin Resistance, Metabolic Syndrome
Interventions
Rifaximin SSD, Placebo
Drug · Other
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Sep 20, 2026, 9:21 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

NCT06597019
View directory record Official record
Conditions
Familial Hypercholesterolemia - Heterozygous
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
9
States / cities
San Francisco, California • Washington D.C., District of Columbia • Boca Raton, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 20, 2026, 9:21 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)

NCT05694260
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Bempedoic acid
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
8
States / cities
Los Angeles, California • West Covina, California • Boca Raton, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 20, 2026, 9:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Habitual Diet and Avocado Trial

NCT03528031
View directory record Official record
Conditions
Intra-abdominal Fat, Metabolic Syndrome, High Cholesterol, Triglycerides High, Diet Habit, High Blood Sugar, Liver Fat, Dietary Modification, HDL Cholesterol, Low Serum, Cardiovascular Diseases, High Density Lipoprotein Deficiency, Low-density-lipoprotein-type, Cardiovascular Risk Factor, Diabetes
Interventions
Intervention Daily Avocado
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
25 Years and older
Enrollment
1,008 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
4
States / cities
Loma Linda, California • Los Angeles, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Sep 20, 2026, 9:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Almonds on Cardiovascular Risk Factors

NCT01101230
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Almonds
Other
Lead sponsor
Penn State University
Other
Eligibility
30 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 20, 2026, 9:21 AM EDT
Completed Not applicable Interventional

Regeneron 1331 Kinetics Sub-Study HoFH

NCT04722068
View directory record Official record
Conditions
Hypercholesterolemia, Familial
Interventions
Kinetics test
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Sep 20, 2026, 9:21 AM EDT
Completed Not applicable Interventional

Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)

NCT03887520
View directory record Official record
Conditions
Cardiovascular Disease and Lipoprotein(a)
Interventions
Blood draw for Lp(a)
Diagnostic Test
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
49,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
180
States / cities
Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 150 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Sep 20, 2026, 9:21 AM EDT
Recruiting Phase 2 Interventional

Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels

NCT06496243
View directory record Official record
Conditions
Dyslipidemias
Interventions
obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 20, 2026, 9:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Family Research Study: Metabolism of Fats and Proteins in Specific Ethnic Groups

NCT00853775
View directory record Official record
Conditions
Healthy, Heart Disease
Interventions
No intervention, observational study
Other
Lead sponsor
University of California, Davis
Other
Eligibility
6 Years and older
Enrollment
325 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Mather, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 20, 2026, 9:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Consuming Palm Oil With Different Macronutrient Intakes on Blood Lipids

NCT02922062
View directory record Official record
Conditions
Cardiovascular Diseases, Inflammation
Interventions
Canola Oil, Palm Oil, Butter
Other
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Sep 20, 2026, 9:21 AM EDT
Active, not recruiting Phase 3 Interventional

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

NCT05581303
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Placebo, Olpasiran
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
7,297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
133
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 112 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 20, 2026, 9:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Niacin on Transport of HDL and Relationship to Atherogenic Lipoproteins and Lipolysis

NCT01250990
View directory record Official record
Conditions
Dyslipidemias
Interventions
Niacin, Placebo
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Sep 20, 2026, 9:21 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Shake It Up: Lipidomics of Lipoproteins and Diet

NCT04120220
View directory record Official record
Conditions
Overweight
Interventions
Heavy Cream, Soybean Oil
Other
Lead sponsor
USDA Grand Forks Human Nutrition Research Center
Federal
Eligibility
18 Years to 60 Years · Male only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Sep 20, 2026, 9:21 AM EDT
Completed Phase 3 Interventional Results available

Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

NCT02833844
View directory record Official record
Conditions
Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
Interventions
Evolocumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
20
States / cities
Los Angeles, California • Hartford, Connecticut • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 20, 2026, 9:21 AM EDT
Not listed Not applicable Interventional

The Effects of ProAlgaZyme on HDL Cholesterol in Individuals With Metabolic Syndrome

NCT00518960
View directory record Official record
Conditions
Metabolic Syndrome, Hyperlipidemia
Interventions
ProAlgaZyme
Drug
Lead sponsor
Health Enhancement Products, Inc.
Industry
Eligibility
40 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Edina, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2007 · Synced Sep 20, 2026, 9:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol

NCT01959971
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
alirocumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Sep 20, 2026, 9:21 AM EDT
Completed No phase listed Observational

Postprandial Lipoproteins and Atherosclerosis

NCT00005263
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Heart Diseases, Carotid Artery Diseases, Myocardial Ischemia
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 1995
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Sep 20, 2026, 9:21 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity

NCT05700916
View directory record Official record
Conditions
Dyslipidemias, Obesity
Interventions
Milk Polar Lipid-Rich Dairy Powder, Dairy Powder
Drug · Dietary Supplement
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 70 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 20, 2026, 9:21 AM EDT
Terminated No phase listed Observational

Protein and Phospholipid Analysis of HDL in Patients With Very High Serum Levels of HDL-C

NCT00525083
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 20, 2026, 9:21 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol

NCT00768274
View directory record Official record
Conditions
Dyslipidemia, Atherosclerosis, Acute Coronary Syndrome, Cardiovascular Disease
Interventions
RVX000222, Placebo
Drug
Lead sponsor
Resverlogix Corp
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Sep 20, 2026, 9:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Walnuts on Central Blood Pressure, Arterial Stiffness Indices, Lipoproteins, and Other CVD Risk Factors

NCT02210767
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Walnut Diet, Walnut Control Diet, Low ALA Diet
Other
Lead sponsor
Penn State University
Other
Eligibility
30 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 20, 2026, 9:21 AM EDT
Recruiting Phase 3 Interventional

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

NCT07157774
View directory record Official record
Conditions
Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Interventions
Muvalaplin, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
10,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
159
States / cities
Birmingham, Alabama • Apache Junction, Arizona • Gilbert, Arizona + 129 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 20, 2026, 9:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Thermic & Lipemic Properties of Dietary Carbohydrates

NCT01354574
View directory record Official record
Conditions
Exogenous Obesity, Dietary Modification
Interventions
High Glycemic Index meals, Low Glycemic Index meals
Other
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
18 Years to 48 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Sep 20, 2026, 9:21 AM EDT